Sermorelin Side Effects: What Research Studies Reveal About Its Safety

Sermorelin is a synthetic peptide studied for its effects on growth hormone (GH) secretion. It works by activating growth hormone-releasing hormone (GHRH) receptors in the pituitary gland, which stimulate the release of the body’s own growth hormone.

But what are the side effects of sermorelin, and what does scientific research actually tell us about its safety?

Historical clinical studies have reported injection-site reactions, facial flushing, headaches, dizziness, and other temporary symptoms. However, the available research also has important limitations, particularly when evaluating long-term effects in healthy adults.

Sermorelin was previously available as an FDA-approved prescription medicine under the name GEREF. Although those products were later discontinued, the FDA determined that their withdrawal was not related to safety or effectiveness concerns.

This article explains the reported side effects of sermorelin, its effects on the growth hormone pathway, possible long-term concerns, and the scientific evidence available.

Key Takeaways

• Injection-site reactions: Pain, redness, and swelling were among the most frequently reported effects in historical sermorelin studies.
• Headaches and flushing: Some participants experienced headaches, dizziness, facial flushing, or sleepiness.
• Allergic reactions: Hypersensitivity reactions are possible, including itching and difficulty swallowing.
• Growth hormone signaling: Sermorelin stimulates endogenous GH secretion, which can influence IGF-1 production.
• Long-term safety: Evidence is limited, particularly for anti-aging, muscle development, and other unapproved uses.
• FDA history: GEREF was previously FDA-approved but was discontinued for reasons unrelated to safety or effectiveness.
• Research-grade products: Clinical findings involving pharmaceutical sermorelin do not establish the safety of research-use-only products.

What Is Sermorelin?

Sermorelin is a synthetic peptide containing 29 amino acids.

It is based on the first 29 amino acids of naturally occurring human growth hormone-releasing hormone (GHRH).

GHRH is produced in the hypothalamus and helps regulate growth hormone secretion from the anterior pituitary gland.

Sermorelin acts as a GHRH receptor agonist, meaning it binds to and activates receptors responsible for stimulating GH release.

Unlike recombinant human growth hormone, sermorelin does not directly supply GH.

Instead, it stimulates the pituitary gland’s existing growth hormone secretion pathway.

Researchers have studied sermorelin in several settings, including growth hormone deficiency, endocrine testing, and the regulation of GH secretion.

Sermorelin’s basic characteristics

Researchers interested in peptide mechanisms can also explore educational resources on the Orion Peptides official website.

How Does Sermorelin Work?

Understanding how sermorelin works helps explain why researchers investigate its possible adverse effects.

Sermorelin activates the growth hormone-releasing hormone receptor on specialized cells called somatotrophs.

These cells are located in the anterior pituitary gland.

When sermorelin binds to GHRH receptors, it activates an intracellular signaling pathway involving a stimulatory G protein, adenylyl cyclase, cyclic AMP (cAMP), and protein kinase A (PKA).

This signaling contributes to the release of stored growth hormone.

GH then acts on different tissues, including the liver, where it promotes the production of insulin-like growth factor-1 (IGF-1).

The process can be summarized as follows:

Sermorelin → GHRH receptor activation → cAMP signaling → GH secretion → IGF-1 production

Because sermorelin activates an endogenous hormone pathway, researchers must consider both effects associated with the peptide itself and possible downstream effects of increased GH or IGF-1 signaling.

However, risks documented for other GH-related drugs should not automatically be attributed to sermorelin without supporting evidence.

What Are the Most Common Sermorelin Side Effects?

Historical clinical research provides the strongest direct information about sermorelin’s reported adverse effects.

A 1999 scientific review examined sermorelin’s use in diagnosing and treating growth hormone deficiency in children.

The review described sermorelin as generally well tolerated in the populations studied, with temporary facial flushing and injection-site pain among the most commonly reported adverse events.

Other drug information sources identify headache, dizziness, sleepiness, and localized injection reactions.

Commonly reported and documented side effects

The frequency of these effects is not established across every sermorelin preparation or research population.

Researchers should avoid interpreting this table as a prediction of how frequently an adverse effect will occur in a healthy adult.

Research reference: Sermorelin: A Review of Its Use in Children With Growth Hormone Deficiency

1. Injection-Site Reactions

Injection-site reactions were among the most frequently reported adverse effects in historical sermorelin studies.

Reported symptoms included:

• Pain at the injection site
• Redness
• Swelling
• Local irritation

These reactions were often described as temporary.

In a 1999 review, injection-site discomfort was identified as one of the main tolerability concerns associated with sermorelin administration.

However, injection-site reactions can have different causes, including the pharmaceutical formulation, administration conditions, and individual sensitivity.

Research-grade materials have additional quality considerations because analytical peptide purity does not establish that a product is sterile or suitable for injection.

The clinical tolerability of a previously approved pharmaceutical product cannot be applied to an unapproved research-grade vial.

2. Facial Flushing and Headaches

Facial flushing is another adverse effect reported in sermorelin research.

Flushing generally refers to a temporary feeling of warmth or visible redness, particularly around the face.

Headaches have also been reported following sermorelin administration.

Historical drug information identifies both symptoms among possible reactions.

However, the mechanisms responsible for these effects have not been fully established.

It would be inaccurate to claim that every headache or episode of flushing is directly caused by increased growth hormone secretion.

The relationship may involve several physiological responses, and individual study findings should be considered separately.

3. Dizziness, Sleepiness, and Restlessness

Some drug information sources identify dizziness, sleepiness, and difficulty remaining still as less common adverse effects associated with sermorelin.

These findings are based mainly on historical clinical experience.

The available evidence does not establish how often such reactions occur with current preparations marketed for research or compounding.

It also does not establish whether these effects are related to the peptide itself, downstream hormonal changes, or other factors in every case.

Researchers should describe them as reported adverse effects rather than predictable outcomes.

4. Allergic Reactions and Hypersensitivity

Hypersensitivity is another safety consideration.

Drug information for sermorelin identifies itching and difficulty swallowing among symptoms that require medical attention.

Allergic reactions can vary in severity.

Potential warning signs of a serious reaction include difficulty breathing, swelling of the face or throat, and difficulty swallowing.

These symptoms require immediate medical evaluation.

It is important to distinguish a temporary local injection-site reaction from a potentially serious systemic allergic reaction.

Historical safety information does not establish that every sermorelin formulation has an identical hypersensitivity risk.

Can Sermorelin Affect Blood Sugar Levels?

Growth hormone plays an important role in glucose metabolism.

Changes in GH signaling can influence insulin sensitivity and blood glucose regulation.

Because sermorelin stimulates endogenous GH secretion, its effects on glucose metabolism are scientifically relevant.

However, there is limited direct evidence establishing the frequency or magnitude of clinically important glucose changes caused by sermorelin alone, particularly during long-term use in healthy adults.

A key distinction is that results from recombinant GH or other GHRH analogs cannot automatically be applied to sermorelin.

Different compounds have different pharmacokinetics, clinical evidence, and treatment exposures.

For this reason, changes in blood glucose should be discussed as a biologically plausible concern requiring further investigation, rather than a proven common sermorelin side effect.

Does Sermorelin Cause Water Retention or Joint Pain?

Water retention, swelling, and joint discomfort are associated with some therapies that increase GH activity.

This raises a reasonable research question about whether sermorelin could produce similar effects under certain conditions.

However, the evidence is more limited for sermorelin itself.

A 2024 FDA presentation described a spontaneous adverse-event report involving joint pain in a person who had received a compounded product containing both ipamorelin and sermorelin.

Because the preparation contained more than one active compound, that report does not establish sermorelin as the cause.

Spontaneous reports also cannot reliably determine the frequency of a reaction.

Researchers should therefore distinguish between:

• Directly reported sermorelin adverse effects
• Effects associated with other GH-related medicines
• Adverse-event reports involving combination products
• Theoretical effects based on hormone signaling

This distinction is important when evaluating the available evidence.

Can Sermorelin Increase IGF-1 Too Much?

IGF-1 is a hormone involved in growth and metabolic regulation.

Growth hormone stimulates IGF-1 production, especially in the liver.

Since sermorelin activates the GH secretion pathway, it can influence downstream IGF-1 levels.

A retrospective study published in 2017 examined a combination of sermorelin, GHRP-2, and GHRP-6 among men receiving testosterone therapy.

The researchers reported changes in IGF-1 concentrations.

However, the study involved a combination of growth hormone secretagogues and included only a small number of participants meeting its strict analysis criteria.

It therefore cannot establish the independent effect of sermorelin or determine long-term safety.

The broader GH–IGF-1 pathway is relevant to concerns about excessive hormone exposure.

Still, researchers should not assign a specific risk percentage to sermorelin without direct evidence.

Research reference: Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises IGF-1 Levels

What Are the Possible Long-Term Side Effects of Sermorelin?

Long-term safety is one of the biggest areas of uncertainty in sermorelin research.

Historical clinical studies evaluated sermorelin primarily in children with growth hormone deficiency or in endocrine diagnostic settings.

Those studies do not establish the safety of long-term use in healthy adults.

They also do not establish safety for applications involving anti-aging, athletic performance, or muscle development.

Areas requiring further research

These uncertainties should not be confused with proof that sermorelin causes each listed condition.

Instead, they identify questions that existing studies have not adequately answered.

Is Sermorelin Safe for Long-Term Use?

There is not enough high-quality evidence to establish sermorelin’s long-term safety across different adult populations.

Historical pediatric studies and diagnostic use provide useful information about tolerability under specific conditions.

However, research involving children with growth hormone deficiency cannot be generalized to healthy adults.

Likewise, the absence of serious adverse events in a small study does not prove that uncommon or delayed complications cannot occur.

Longer and better-controlled clinical studies would be needed to assess extended exposure and its effects on metabolic, endocrine, and cardiovascular outcomes.

Is Sermorelin FDA-Approved?

Sermorelin has an unusual regulatory history.

The FDA previously approved sermorelin acetate under the brand name GEREF.

Different GEREF formulations were approved for evaluating growth hormone secretion and for treating certain children with growth hormone deficiency.

The products were later discontinued.

In a Federal Register notice published on March 4, 2013, the FDA determined that the relevant GEREF products were not withdrawn for reasons of safety or effectiveness.

This distinction is important.

The discontinuation did not mean that the FDA had determined sermorelin to be unsafe.

However, historical approval does not mean every sermorelin product currently sold online is FDA-approved.

Research-grade sermorelin is not equivalent to an FDA-approved pharmaceutical preparation.

Researchers should also distinguish between previously approved products and current compounded preparations, which are subject to different legal and regulatory requirements.

Official FDA reference: Federal Register: GEREF Was Not Withdrawn for Safety or Effectiveness Reasons

Sermorelin vs. Tesamorelin: Do They Have the Same Side Effects?

Sermorelin and tesamorelin both activate GHRH receptors, but they are structurally different compounds.

Sermorelin contains 29 amino acids.

Tesamorelin contains the 44-amino-acid GHRH sequence with an N-terminal chemical modification.

Both stimulate endogenous GH secretion, but their pharmacokinetic properties and clinical evidence differ.

Tesamorelin’s clinical studies provide more extensive information about several metabolic and endocrine outcomes.

However, it would not be scientifically accurate to conclude that one peptide is safer than the other based solely on separate trials.

The studies involved different populations, formulations, and endpoints.

For a detailed look at the related mechanism, see Orion Peptides’ educational article on tesamorelin structure, function, and research.

Why Peptide Quality Matters in Sermorelin Research

The accuracy of laboratory results depends partly on the identity and quality of the material being studied.

If a peptide sample contains unexpected impurities or degradation products, those substances can introduce additional variables into an experiment.

For sermorelin research, scientists may evaluate identity and purity using analytical techniques such as:

• High-performance liquid chromatography (HPLC)
• Liquid chromatography-mass spectrometry (LC-MS)
• Other appropriate characterization methods

HPLC is commonly used to evaluate chromatographic purity.

Mass spectrometry can provide evidence supporting molecular identity.

However, a high HPLC purity result does not establish sterility, clinical safety, or suitability for injection.

A Certificate of Analysis (COA) should be interpreted according to the specific tests performed.

Researchers can learn more through Orion Peptides’ guides to research peptide quality standards and third-party testing for research peptides.

Frequently Asked Questions About Sermorelin Side Effects

What are the most common side effects of sermorelin?

Historical studies most commonly reported temporary injection-site reactions and facial flushing. Other reported effects include headache, dizziness, sleepiness, and restlessness.

Can sermorelin cause headaches?

Yes. Headache has been reported as a possible adverse effect. However, the available evidence does not establish how frequently headaches occur across different sermorelin formulations and study populations.

Does sermorelin cause joint pain?

Joint pain is a potential concern when evaluating GH-related compounds, but the direct evidence for sermorelin alone is limited. A reported case involving a combined ipamorelin and sermorelin product does not establish that sermorelin caused the symptom.

Can sermorelin affect blood sugar?

Sermorelin stimulates the GH pathway, which can influence glucose regulation. However, there is insufficient direct evidence to determine the frequency or severity of blood sugar changes associated with sermorelin alone.

Does sermorelin cause water retention?

Fluid retention is a recognized concern with some GH-related therapies. However, its frequency with sermorelin specifically has not been adequately established.

Can sermorelin cause an allergic reaction?

Yes. Hypersensitivity reactions are possible. Difficulty breathing, throat swelling, or difficulty swallowing requires immediate medical attention.

Is sermorelin safer than growth hormone?

There is insufficient direct comparative evidence to conclude that sermorelin is safer than recombinant human growth hormone. Their mechanisms differ, but mechanistic differences alone do not establish superior safety.

Is sermorelin safe for anti-aging purposes?

There is not enough high-quality clinical evidence to establish sermorelin’s safety or effectiveness for anti-aging purposes in otherwise healthy adults.

Was sermorelin banned by the FDA?

No. Sermorelin was previously marketed under the FDA-approved brand GEREF. Those products were discontinued, and the FDA later determined that the withdrawal was not for safety or effectiveness reasons. This does not mean current research-grade products are FDA-approved.

What happens if sermorelin increases IGF-1?

IGF-1 increases are a downstream effect of GH-axis stimulation. The clinical significance depends on factors such as the magnitude and duration of the increase and the population studied. The long-term consequences of persistent elevation during sermorelin use are not adequately established.

Conclusion

Sermorelin is a synthetic GHRH analog that stimulates the pituitary gland to release endogenous growth hormone.

Historical clinical studies have documented several adverse effects, particularly injection-site reactions and temporary facial flushing. Headaches, dizziness, sleepiness, and hypersensitivity symptoms have also been reported.

However, the available safety evidence has important limitations.

Most direct clinical studies involved specific diagnostic or pediatric growth hormone deficiency settings. These findings do not establish the safety of long-term sermorelin use in healthy adults.

Other concerns, including effects on glucose metabolism, fluid balance, and prolonged IGF-1 elevation, require careful interpretation because direct sermorelin-specific evidence remains limited.

For laboratory researchers, understanding these findings is useful when studying GHRH receptor signaling and growth hormone regulation.

Additional educational resources on peptide structure, quality testing, and research applications are available through Orion Peptides.

Scientific References

1. Prakash A, Goa KL. (1999). Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children With Idiopathic Growth Hormone Deficiency. BioDrugs. https://pubmed.ncbi.nlm.nih.gov/18031173/
2. U.S. Food and Drug Administration. (2013). Determination That GEREF (Sermorelin Acetate) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
3. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. (2017). https://pubmed.ncbi.nlm.nih.gov/28830317/
4. Growth-Hormone-Releasing Factor for Growth Hormone Deficiency. (1999). https://pubmed.ncbi.nlm.nih.gov/9924487/
5. Mayo Clinic. Sermorelin (Injection Route): Side Effects. https://www.mayoclinic.org/drugs-supplements/sermorelin-injection-route/side-effects/drg-20065923

Research Disclaimer: This article is provided for scientific and educational purposes only. Research-use-only sermorelin is not intended for human or veterinary administration. Human clinical findings discussed here relate to historically studied pharmaceutical preparations and cannot be used to establish the safety of research-grade products. This article is not medical advice.